Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

[1]  E. Unanue,et al.  Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Bohn,et al.  Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. , 1985, Biochimica et biophysica acta.

[3]  P. Suter,et al.  Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. , 1996, American journal of respiratory and critical care medicine.

[4]  B. Dijkmans,et al.  Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. , 1997, The Journal of rheumatology.

[5]  M. Feldmann,et al.  Role of Tyrosine Kinase Enzymes in TNF‐α and IL‐1 Induced Expression of ICAM‐1 and VCAM‐1 on Human Umbilical Vein Endothelial Cells , 1997, Scandinavian journal of immunology.

[6]  M. Feldmann,et al.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[7]  F. Breedveld,et al.  Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.

[8]  G. de Saint Basile,et al.  Perforin: more than just an effector molecule. , 2000, Immunology today.

[9]  M. Feldmann,et al.  Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[10]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[11]  R. Riley,et al.  Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. , 2001, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[12]  D. Dickens,et al.  Etanercept in the treatment of macrophage activation syndrome. , 2001, The Journal of rheumatology.

[13]  F. Martinon,et al.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.

[14]  R. Schneider,et al.  Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. , 2003, The Journal of rheumatology.

[15]  S. Ebong,et al.  Suppressor of Cytokine Signaling 3 Regulates Proliferation and Activation of T-helper Cells* , 2003, Journal of Biological Chemistry.

[16]  Donald Metcalf,et al.  SOCS3 negatively regulates IL-6 signaling in vivo , 2003, Nature Immunology.

[17]  Yi Guan,et al.  Lung pathology of fatal severe acute respiratory syndrome , 2003, The Lancet.

[18]  C. Scagnolari,et al.  Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons , 2004, Antiviral therapy.

[19]  Donald E. Mager,et al.  Receptor-Mediated Pharmacokinetic/Pharmacodynamic Model of Interferon-β 1a in Humans , 2002, Pharmaceutical Research.

[20]  Peter B. Jahrling,et al.  Interferon-β 1a and SARS Coronavirus Replication , 2004, Emerging infectious diseases.

[21]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[22]  C. Dinarello.  Blocking IL-1 in systemic inflammation , 2005, The Journal of experimental medicine.

[23]  Michel Theron,et al.  An interferon‐γ‐related cytokine storm in SARS patients† , 2004, Journal of medical virology.

[24]  Y. Lau,et al.  Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells , 2005, Blood.

[25]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[26]  Paul Garner,et al.  SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.

[27]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[28]  T. Junt,et al.  Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. , 2006, Blood.

[29]  J. Narbutt,et al.  Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients , 2006, Lupus.

[30]  L. Teyton,et al.  Interleukin-10 determines viral clearance or persistence in vivo , 2006, Nature Medicine.

[31]  R. Lafyatis,et al.  Antimalarial agents: closing the gate on Toll-like receptors? , 2006, Arthritis and rheumatism.

[32]  F. Martinon,et al.  Inflammatory caspases and inflammasomes: master switches of inflammation , 2007, Cell Death and Differentiation.

[33]  Julian Druce,et al.  Induction of Apoptosis by the Severe Acute Respiratory Syndrome Coronavirus 7a Protein Is Dependent on Its Interaction with the Bcl-XL Protein , 2007, Journal of Virology.

[34]  S. Kalia,et al.  New concepts in antimalarial use and mode of action in dermatology , 2007, Dermatologic therapy.

[35]  B. Fautrel.  Adult-onset Still disease. , 2008, Best practice & research. Clinical rheumatology.

[36]  H. Ören,et al.  Etanercept for therapy‐resistant macrophage activation syndrome , 2008, Pediatric blood & cancer.

[37]  D. Venzon,et al.  Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets , 2008, The Journal of experimental medicine.

[38]  T. Sasazuki,et al.  Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry , 2008, Proceedings of the National Academy of Sciences.

[39]  J. Ting,et al.  The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. , 2009, Immunity.

[40]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[41]  S. Perlman,et al.  Coronaviruses post-SARS: update on replication and pathogenesis , 2009, Nature Reviews Microbiology.

[42]  Christian Drosten,et al.  Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 , 2009, Journal of Virology.

[43]  G. Sterba,et al.  Macrophage activation syndrome induced by etanercept in a patient with systemic sclerosis. , 2010, The Israel Medical Association journal : IMAJ.

[44]  R. Hotchkiss,et al.  IL-7 Promotes T Cell Viability, Trafficking, and Functionality and Improves Survival in Sepsis , 2010, The Journal of Immunology.

[45]  Gunther Hartmann,et al.  Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1β production , 2010, Nature Immunology.

[46]  E. Kim,et al.  Immunotherapeutic effects of IL-7 during a chronic viral infection in mice. , 2011, Blood.

[47]  A. Filipovich.  The expanding spectrum of hemophagocytic lymphohistiocytosis , 2011, Current opinion in allergy and clinical immunology.

[48]  U. Švajger,et al.  Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines , 2011, The Journal of Immunology.

[49]  W. Reith,et al.  Plasmacytoid dendritic cells control T-cell response to chronic viral infection , 2012, Proceedings of the National Academy of Sciences.

[50]  A. Thomsen,et al.  Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus Invasion , 2012, Journal of Virology.

[51]  R. Priori,et al.  IL-18 Serum Level in Adult Onset Still's Disease: A Marker of Disease Activity , 2012, International journal of inflammation.

[52]  J. Wolchok,et al.  Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. , 2012, Blood.

[53]  C. Bokemeyer,et al.  Critical Imbalance of TNF-α and Soluble TNF Receptor 1 in a Patient with Macrophage Activation Syndrome: Potential Implications for Diagnostics and Treatment , 2012, Acta Haematologica.

[54]  W. Seeger,et al.  Macrophage-expressed IFN-β Contributes to Apoptotic Alveolar Epithelial Cell Injury in Severe Influenza Virus Pneumonia , 2013, PLoS pathogens.

[55]  Ruth R. Montgomery,et al.  Age-dependent dysregulation of innate immunity , 2013, Nature Reviews Immunology.

[56]  H. Feldmann,et al.  Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin , 2013, Scientific Reports.

[57]  Kwok-Hung Chan,et al.  Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. , 2013, The Journal of general virology.

[58]  Y. Shoenfeld,et al.  The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome , 2013, BMC Medicine.

[59]  A. López-Guillermo,et al.  Adult haemophagocytic syndrome , 2014, The Lancet.

[60]  P. Sève,et al.  Adult-onset Still's disease. , 2014, Autoimmunity reviews.

[61]  D. Maucort-Boulch,et al.  Adult-Onset Still Disease , 2014, Medicine.

[62]  G. Schulert,et al.  Macrophage activation syndrome and cytokine-directed therapies. , 2014, Best practice & research. Clinical rheumatology.

[63]  C. Rice,et al.  Interferon-stimulated genes: a complex web of host defenses. , 2014, Annual review of immunology.

[64]  Z. Memish,et al.  Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study , 2014, The Lancet Infectious Diseases.

[65]  Z. Memish,et al.  Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study , 2014, International Journal of Infectious Diseases.

[66]  Jaume Torres,et al.  Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome , 2015, Virology.

[67]  G. Schulert,et al.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. , 2015, Annual review of medicine.

[68]  A. Oxenius,et al.  Regulation of antiviral T cell responses by type I interferons , 2015, Nature Reviews Immunology.

[69]  F. Martinon,et al.  Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart , 2014, Immunologic Research.

[70]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[71]  A. Rizzo,et al.  Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. , 2015, Autoimmunity reviews.

[72]  Jian-Piao Cai,et al.  Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset , 2015, The Journal of infectious diseases.

[73]  H. Akpovwa.  Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity , 2016, Cell biochemistry and function.

[74]  É. Azoulay,et al.  Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis. , 2016, Chest.

[75]  M. Lederman,et al.  Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  Richard L. Amdur,et al.  Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial* , 2016, Critical care medicine.

[77]  Chengjun Li,et al.  The effect of inhibition of PP1 and TNFα signaling on pathogenesis of SARS coronavirus , 2016, BMC Systems Biology.

[78]  M. Dreux,et al.  Cell-Cell Sensing of Viral Infection by Plasmacytoid Dendritic Cells , 2016, Journal of Virology.

[79]  J. Lieberman,et al.  Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores , 2016, Nature.

[80]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[81]  C. Wouters,et al.  Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities , 2016, British journal of haematology.

[82]  Akira Ishii,et al.  Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review , 2016, Case reports in medicine.

[83]  E. Wherry,et al.  Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. , 2016, Blood.

[84]  F. De Benedetti,et al.  Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome , 2017, Pediatric Rheumatology.

[85]  A. Belot,et al.  Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review , 2018, Clinical Reviews in Allergy & Immunology.

[86]  I. Ben-Zvi,et al.  Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2017, Arthritis & rheumatology.

[87]  J. Kelsen,et al.  Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. , 2017, The Journal of allergy and clinical immunology.

[88]  C. Johansson,et al.  Type I Interferons as Regulators of Lung Inflammation , 2017, Front. Immunol..

[89]  Min Wang,et al.  SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death , 2018, Cell Death & Disease.

[90]  D. Foell,et al.  Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. , 2018, Blood.

[91]  Zaina T. Al-Salama.  Emapalumab: First Global Approval , 2019, Drugs.

[92]  R. Hotchkiss,et al.  Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. , 2018, JCI insight.

[93]  Rajaa Al-Raddadi,et al.  Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome , 2017, American journal of respiratory and critical care medicine.

[94]  L. Arnaud,et al.  Targeting interferons and their pathways in systemic lupus erythematosus. , 2017, Autoimmunity reviews.

[95]  G. Guyatt,et al.  Corticosteroid therapy for sepsis: a clinical practice guideline , 2018, British Medical Journal.

[96]  F. Locke,et al.  Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities , 2018, BioDrugs.

[97]  F. Spertini,et al.  Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease , 2017, Annals of the rheumatic diseases.

[98]  Rajanish Giri,et al.  Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease , 2018, ACS omega.

[99]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[100]  Z. Memish,et al.  Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial , 2018, Trials.

[101]  M. Croft,et al.  TNF activity and T cells. , 2018, Cytokine.

[102]  R. Tattersall,et al.  Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment , 2019, Rheumatology.

[103]  K. Nichols,et al.  The Immunology of Macrophage Activation Syndrome , 2019, Front. Immunol..

[104]  S. Ohlman,et al.  Anakinra in children and adults with Still’s disease , 2019, Rheumatology.

[105]  M. Borca,et al.  The Role of Interleukin 6 During Viral Infections , 2019, Front. Microbiol..

[106]  C. Shi,et al.  SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes , 2019, Cell Death Discovery.

[107]  Y. Jamilloux,et al.  Les inhibiteurs de JAK : perspectives pour la médecine interne , 2019 .

[108]  Hanan H Balkhy,et al.  Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[109]  Hong Sun,et al.  Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV , 2019, Viruses.

[110]  K. Nichols,et al.  Mechanisms of Action of Ruxolitinib in Murine Models of Hemophagocytic Lymphohistiocytosis. , 2019, Blood.

[111]  N. Berliner,et al.  Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. , 2019, Blood.

[112]  P. Sève,et al.  JAK inhibitors for the treatment of autoimmune and inflammatory diseases. , 2019, Autoimmunity reviews.

[113]  M. Dreux,et al.  Plasmacytoid Dendritic Cells and Infected Cells Form an Interferogenic Synapse Required for Antiviral Responses. , 2019, Cell host & microbe.

[114]  Gizem Yıldız,et al.  IL-1β blockade in periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: case-based review , 2019, Rheumatology International.

[115]  K. Yuen,et al.  Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3‐dependent ubiquitination of ASC , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[116]  E. Giamarellos‐Bourboulis,et al.  Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis , 2019, Front. Immunol..

[117]  Takeshi Ichinohe,et al.  Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome , 2019, Front. Microbiol..

[118]  D. Teachey,et al.  Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome , 2019, Expert review of clinical immunology.

[119]  Andrew J. Oler,et al.  Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. , 2019, The Journal of clinical investigation.

[120]  Özgür A. Onur,et al.  In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy , 2019, HemaSphere.

[121]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[122]  Zhenwei Yang,et al.  The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis , 2020, Journal of Infection.

[123]  F. Lu,et al.  Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia , 2020, medRxiv.

[124]  Zhaohui Zheng,et al.  SARS-CoV-2 invades host cells via a novel route: CD147-spike protein , 2020, bioRxiv.

[125]  W. Xu,et al.  RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion , 2020, Cellular & Molecular Immunology.

[126]  D. Raoult,et al.  Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial , 2020, medRxiv.

[127]  J. Qu,et al.  Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial , 2020, medRxiv.

[128]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[129]  F. A. Lagunas-Rangel,et al.  High IL‐6/IFN‐γ ratio could be associated with severe disease in COVID‐19 patients , 2020, Journal of medical virology.

[130]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[131]  D. McGonagle,et al.  The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease , 2020, Autoimmunity Reviews.

[132]  Vineet D. Menachery,et al.  Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV , 2020, Journal of Virology.

[133]  Mandeep R. Mehra,et al.  COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal , 2020, The Journal of Heart and Lung Transplantation.

[134]  Minghao Fang,et al.  Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia , 2020, Signal transduction and targeted therapy.

[135]  Ming Yang.  Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection , 2020 .

[136]  X. Bian,et al.  [A pathological report of three COVID-19 cases by minimally invasive autopsies]. , 2020, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[137]  Dong Liu,et al.  Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.

[138]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[139]  Yong-tang Zheng,et al.  Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[140]  Y. Shoenfeld.  Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning , 2020, Autoimmunity Reviews.

[141]  Lei Liu,et al.  Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome , 2020, medRxiv.

[142]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[143]  Jacques Fantini,et al.  Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection , 2020, International Journal of Antimicrobial Agents.

[144]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[145]  E. Coomes,et al.  Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis , 2020, medRxiv.

[146]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[147]  Suxin Wan,et al.  Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) , 2020, medRxiv.

[148]  R. Giacomelli,et al.  Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? , 2020, Autoimmunity Reviews.

[149]  Zhiyong Ma,et al.  Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia , 2020, The Journal of infectious diseases.

[150]  Dong Men,et al.  Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients , 2020, medRxiv.

[151]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[152]  Y. Yazdanpanah,et al.  Type 1 interferons as a potential treatment against COVID-19 , 2020, Antiviral Research.

[153]  T. W. Wampler Muskardin.  Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019 , 2020, ACR open rheumatology.

[154]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[155]  S. Antinori,et al.  COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? , 2020, Clinical and experimental rheumatology.

[156]  J. Leonardi-Bee,et al.  Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. , 2020, Critical care medicine.

[157]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[158]  P. Ravaud,et al.  No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial , 2020, medRxiv.

[159]  K. Brengel-Pesce,et al.  Type I IFN immunoprofiling in COVID-19 patients , 2020, Journal of Allergy and Clinical Immunology.

[160]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[161]  Malik Peiris,et al.  Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.

[162]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[163]  N. Chaput,et al.  Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report , 2020, Annals of Oncology.

[164]  Huan Li,et al.  Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis , 2020, The Journal of Infection.

[165]  C. Delaugerre,et al.  No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection , 2020, Médecine et Maladies Infectieuses.

[166]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[167]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[168]  Hongzhou Lu,et al.  [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[169]  Zhiguang Zhou,et al.  Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? , 2020, Journal of Autoimmunity.

[170]  F. Ingegnoli,et al.  COVID-19 infection and rheumatoid arthritis: Faraway, so close! , 2020, Autoimmunity Reviews.

[171]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.

[172]  E. Fish,et al.  Interferon-a2b treatment for COVID-19 , 2020, medRxiv.

[173]  X. He,et al.  Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol , 2020, Chinese medical journal.

[174]  Q. Bassat,et al.  Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study) , 2020, medRxiv.

[175]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[176]  K. He,et al.  Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection , 2020 .

[177]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[178]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[179]  B. Liang,et al.  Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis , 2020, Journal of Infection.

[180]  Jonathan H. Morgan,et al.  Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support , 2020, medRxiv.

[181]  Z. Meng,et al.  An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area , 2020, medRxiv.

[182]  N. Bashir,et al.  COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses , 2020, Journal of Advanced Research.

[183]  Reem A Mustafa,et al.  Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[184]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[185]  K. Shen,et al.  Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue , 2020, World Journal of Pediatrics.

[186]  A. Perelson,et al.  Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load , 2020, medRxiv.

[187]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[188]  W. Xu,et al.  Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion , 2020, Cellular & Molecular Immunology.

[189]  E. Gertner,et al.  Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome , 2020, ACR open rheumatology.

[190]  Michael Roth,et al.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.

[191]  Matthew Rowland,et al.  Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed , 2020, The Lancet.

[192]  Y. Hu,et al.  On the use of corticosteroids for 2019-nCoV pneumonia , 2020, The Lancet.

[193]  Yuan-qiang Lu,et al.  COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients , 2020, medRxiv.

[194]  R. Alizadeh-Navaei,et al.  Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis , 2020, medRxiv.

[195]  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[196]  Vineet D. Menachery,et al.  Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. , 2020, bioRxiv.

[197]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[198]  M. Shi,et al.  Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients , 2020, Emerging microbes & infections.

[199]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[200]  F. Rivellese,et al.  ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia , 2020, Autoimmunity Reviews.

[201]  A. Vallée,et al.  Interleukin-6 blockade for severe COVID-19 , 2020, medRxiv.

[202]  Huan Li,et al.  Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis , 2020, Journal of Infection.

[203]  J. Rehwinkel,et al.  RIG-I-like receptors: their regulation and roles in RNA sensing , 2020, Nature Reviews Immunology.

[204]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[205]  F. Rieux-Laucat,et al.  Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients , 2020, medRxiv.